News
ONVO
1.000
-2.91%
-0.030
Weekly Report: what happened at ONVO last week (0415-0419)?
Weekly Report · 3d ago
INVO, EZGO and WISA among pre-market losers
Seeking Alpha · 04/18 12:15
INDO, ONVO and HUSA among pre-market losers
InDO, ONVO and HUSA among pre-market losers. Ryvyl -37% on launch of proposed underwritten public offering. Live Nation Entertainment -9% on reports Justice Dept. May file antitrust lawsuit next month. ArcelorMittal -6%.
Seeking Alpha · 04/16 12:28
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Dynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap rose to $3.3 million. Inovio Pharmaceuticals shares fell 24.3% during the session. Akanda shares increased by 23.0% and BioRestorative Therapies shares moved upwards.
Benzinga · 04/16 12:07
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. The company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome. Soligenix, Inc. Shares surged 71.5% after the company was granted orphan drug designation for MarVax.
Benzinga · 04/15 18:11
12 Health Care Stocks Moving In Monday's Intraday Session
Longeveron (NASDAQ:LGVN) stock moved upwards by 44.4% to $2.44 during Monday's regular session. Mobile-health Network shares rose 35.53% during the session. Jaguar Health and Organovo Holdings were the biggest gainers. Marinus Pharma and China SXT Pharmaceuticals were the largest losers.
Benzinga · 04/15 16:31
BUZZ-U.S. STOCKS ON THE MOVE-Cisco Systems, Inspired Entertainment, Spirit Airlines
Dow Jones Industrial Average was up 0.36% at 38,119.77. Goldman Sachs boosted by robust gains. Top three S&P 500 percentage gainers: M&T Bank, Centene, Snap One. Apple down 0.6% after falling in premarket trading.
Reuters · 04/15 16:13
Why Organovo Stock Is Up Today
Organovo Holdings, Inc. Shares are trading higher Monday after the company announced Phase 2 results for FXR314. Organovo shares are moving on heavy trading volume following the release of the results. The company does not pay a dividend but has a number of ways to return value to shareholders.
Benzinga · 04/15 14:56
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
The Dow Jones index gained more than 300 points on Monday. Goldman Sachs Group Inc. Reported better-than-expected first-quarter earnings. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70%. Soligenix, Inc. Shares shot up 98% after being granted orphan drug designation for MarVax.
Benzinga · 04/15 14:00
BUZZ-U.S. STOCKS ON THE MOVE-Encore Wire, Masimo, Goldman Sachs
Wall Street's main stock indexes eyed a higher open on Monday. Dow e-minis up 0.82%, S&P 500 and Nasdaq 100 also up. Goldman Sachs, Encore Wire, Masimo, Lockheed Martin among top stocks on the move. Tensions in the Middle East make investors wary of the U.S.
Reuters · 04/15 13:26
Organovo reports positive mid-stage results for FXR314 in metabolic dysfunction-associated steatohepatitis
Healthcare Organovo reports positive mid-stage results for FXR314 in metabolic dysfunction-associated steatohepatitis. Organovo Holdings, Inc. (ONVO) reports positive results from Phase 2 study of its liver fat content reduction treatment. The drug is also found to be safe and well tolerated.
Seeking Alpha · 04/15 12:51
Market-Moving News for April 15th
Goldman Sachs shares are trading higher. Goldman Sachs reports better-than-expected Q1 earnings and revenues. Longeveron's Lomecel-B accepted for oral presentation at AAIC. Organovo announces Phase 2 results for FXR314 in Alzheimer's disease.
Benzinga · 04/15 12:44
BUZZ-Organovo Holdings up after fatty liver drug meets main goal in mid-stage study
Organovo Holdings up after fatty liver drug meets main goal in mid-stage study. Shares of Organovo Holdings ONVO.O up 31.4% to $1.34 premarket. Co says its experimental drug to treat a type of fatty liver disease met the main goal.
Reuters · 04/15 12:35
UPDATE 2-Organovo's drug significantly reduces liver fat in NASH study
Organovo's drug significantly reduces liver fat in NASH study. Shares of the small biotech firm surged 44% to $1.45 in early trading on Monday. Company's drug reduced liver fat by as much as 22.8% in a mid-stage study of some patients with NASH. The oral drug, FXR314, helped improve liver function.
Reuters · 04/15 12:23
SHARES OF ORGANOVO HOLDINGS UP 19.6% PREMARKET AS FATTY LIVER DISEASE DRUG MEETS MAIN GOAL IN MID-STAGE STUDY
Reuters · 04/15 12:18
Organovo's fatty liver disease drug meets main goal in mid-stage study
Reuters · 04/15 12:13
ORGANOVO HOLDINGS INC: TREATMENT-EMERGENT ADVERSE EVENTS WERE MOSTLY MILD TO MODERATE IN SEVERITY
Reuters · 04/15 12:05
ORGANOVO HOLDINGS-STUDY RESULTS SHOWED STATISTICALLY SIGNIFICANT REDUCTION IN LIVER FAT CONTENT FROM BASELINE IN PATIENTS RECEIVING FXR314 VS PLACEBO
Reuters · 04/15 12:05
Weekly Report: what happened at ONVO last week (0408-0412)?
Weekly Report · 04/15 10:57
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Medical Properties Trust, Inc. Shares jumped 13.1% in today's pre-market trading. The company announced it sold its majority interest in Utah Hospitals. LendingClub Corporation is expected to report earnings for the first quarter 2024 after the closing bell on Tuesday. Allarity Therapeutics shares rose 51% to $3.17 in pre- market trading.
Benzinga · 04/15 09:45
More
Webull provides a variety of real-time ONVO stock news. You can receive the latest news about Organovo Holding through multiple platforms. This information may help you make smarter investment decisions.
About ONVO
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.